Literature DB >> 9560131

Menstrual timing of breast cancer surgery.

A A Hagen1, W J Hrushesky.   

Abstract

PURPOSE AND
DESIGN: This is a critical review of the growing body of data, 32 retrospective studies of the outcomes of 9,665 women published since 1989, relevant to the possibility that the timing of primary breast cancer resection within the menstrual cycle impacts breast cancer recurrence and/or spread and patient survival. This article evaluates and contrasts the adequacy of information and data analysis presented in each publication. The overall purpose of this exercise is to rigorously determine the relative strength of the hypothesis that the menstrual cycle timing of operation impacts outcome and, thereby, to determine whether or not a specific change in the practice of breast surgical oncology can be recommended.
RESULTS: The single most completely reported and thoroughly analyzed series, involving 1,175 young women, indicates that surgical resection timing is likely to be relevant to outcome. Seven additional high-quality studies involving 2,864 women have been most completely reported. While two of these eight find no impact, six (75%) of these studies find that breast cancer outcome is affected by operative timing. Nine of the remaining 24 less-complete studies report a statistically significant effect of operative timing. Among these 15 studies of the fates of more than 5,000 women, the opportune menstrual cycle phase almost invariably includes the putative luteal phase. A large number of retrospective studies of widely varying quality find no outcome difference as a function of resection timing. The adequacy of design of each of four ongoing prospective studies is found lacking.
CONCLUSIONS: Although it is likely that the menstrual cycle phase of operation is relevant to outcome, the nature of the available data cannot allow a clear recommendation of precisely when to operate. It is, therefore, concluded that current retrospective data are inadequate to recommend an immediate change in practice. Prospective studies of this potentially important question are essential. The prospective trials initiated to date will not be able to definitively answer this question because of inadequate chronobiological design. The minimal requirements for adequate prospective study are delineated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560131     DOI: 10.1016/s0002-9610(97)00294-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.

Authors:  A Balsari; P Casalini; E Tagliabue; M Greco; S Pilotti; R Agresti; R Giovanazzi; L Alasio; C Rumio; N Cascinelli; M I Colnaghi; S Ménard
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

2.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

3.  Creation of a stable mammary tumor cell line that maintains fertility-cycle tumor biology of the parent tumor.

Authors:  Shaojin You; Wei Li; Minoru Kobayashi; Yin Xiong; William Hrushesky; Patricia Wood
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Jul-Aug       Impact factor: 2.416

Review 4.  Timing of breast surgery in premenopausal breast cancer patients.

Authors:  Miny Samuel; Khin Lay Wai; Victoria K Brennan; Wei Sean Yong
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

5.  Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions.

Authors:  R R Greb; I Maier; D Wallwiener; L Kiesel
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

6.  Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity.

Authors:  K Shakhar; G Shakhar; E Rosenne; S Ben-Eliyahu
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

7.  The Relationship between Surgery and Phase of the Menstrual Cycle Affects Survival in Breast Cancer.

Authors:  Ali Imran Kucuk; Can Atalay
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

8.  Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study.

Authors:  H Thorpe; S R Brown; J R Sainsbury; T J Perren; V Hiley; M Dowsett; A Nejim; J M Brown
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

9.  An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival.

Authors:  Antoine M Snijders; Sasha Langley; Jian-Hua Mao; Sandhya Bhatnagar; Kathleen A Bjornstad; Chris J Rosen; Alvin Lo; Yurong Huang; Eleanor A Blakely; Gary H Karpen; Mina J Bissell; Andrew J Wyrobek
Journal:  Oncotarget       Date:  2014-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.